We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+1.86%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$54.7B
AUM Growth
+$1.45B
(+2.7%)
Cap. Flow
+$1.02B
Cap. Flow
% of AUM
1.86%
Top 10 Holdings %
Top 10 Hldgs %
17.33%
Holding
3,009
New
39
Increased
2,170
Reduced
725
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity National Information Services
FIS
|
+$65.3M |
| 2 |
Global Payments
GPN
|
+$40.3M |
| 3 |
Microsoft
MSFT
|
+$37.9M |
| 4 |
L3Harris
LHX
|
+$32.8M |
| 5 |
Amazon
AMZN
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APC
Anadarko Petroleum
APC
|
+$64.3M |
| 2 |
RHT
Red Hat Inc
RHT
|
+$57.1M |
| 3 |
TSS
Total System Services, Inc.
TSS
|
+$40M |
| 4 |
WP
Worldpay, Inc.
WP
|
+$39.2M |
| 5 |
LLL
L3 Technologies, Inc.
LLL
|
+$32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.64% |
| 2 | Financials | 15.56% |
| 3 | Healthcare | 12.85% |
| 4 | Consumer Discretionary | 10.31% |
| 5 | Industrials | 10.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1551
Resources Connection
RGP
$151M
| $2.79M | 0.01% |
164,071
+28,933
| +21% | +$487K |
|
|
SPPI
1552
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $2.79M | 0.01% |
335,955
+18,264
| +6% | +$148K |
|
|
MRTX
1553
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.77M | 0.01% |
35,505
+2,015
| +6% | +$189K |
|
|
RTEC
1554
DELISTED
Rudolph Technologies Inc
RTEC
| $2.77M | 0.01% |
104,927
+5,644
| +6% | +$143K |
|
1555
Avantor
AVTR
$8.93B
| $2.76M | 0.01% |
+187,780
| New | +$3.18M |
|
|
WPG
1556
DELISTED
Washington Prime Group Inc.
WPG
| $2.76M | 0.01% |
73,989
+5,492
| +8% | +$181K |
|
1557
Carvana
CVNA
$76.4B
| $2.73M | 0.01% |
207,115
+15,720
| +8% | +$226K |
|
1558
PTC Therapeutics
PTCT
$5.85B
| $2.73M | 0.01% |
80,822
+1,057
| +1% | +$46K |
|
|
FOLD
1559
DELISTED
Amicus Therapeutics
FOLD
| $2.72M | 0.01% |
339,666
+19,791
| +6% | +$215K |
|
1560
Kinsale Capital Group
KNSL
$8.45B
| $2.72M | 0.01% |
26,349
+471
| +2% | +$45.2K |
|
1561
Morningstar
MORN
$7.39B
| $2.71M | 0.01% |
18,557
-297
| -2% | -$45.7K |
|
1562
Moderna
MRNA
$22.2B
| $2.71M | 0.01% |
170,198
+137,924
| +427% | +$2.04M |
|
1563
Laureate Education
LAUR
$5.18B
| $2.71M | 0.01% |
163,431
+23,445
| +17% | +$394K |
|
1564
Marcus Corp
MCS
$948M
| $2.7M | ﹤0.01% |
73,037
+7,208
| +11% | +$248K |
|
1565
Usana Health Sciences
USNA
$285M
| $2.7M | ﹤0.01% |
39,516
+8,710
| +28% | +$585K |
|
1566
PetMed Express
PETS
$42.1M
| $2.69M | ﹤0.01% |
149,065
+45,387
| +44% | +$749K |
|
1567
Preferred Bank
PFBC
$1.26B
| $2.68M | ﹤0.01% |
51,182
+9,294
| +22% | +$473K |
|
1568
Mesa Laboratories
MLAB
$569M
| $2.67M | ﹤0.01% |
11,238
+3,523
| +46% | +$814K |
|
1569
iShares Core S&P Small-Cap ETF
IJR
$112B
| $2.66M | ﹤0.01% |
34,225
+11,395
| +50% | +$882K |
|
1570
Virtus Investment Partners
VRTS
$1.1B
| $2.66M | ﹤0.01% |
24,072
+638
| +3% | +$68.6K |
|
|
DBD
1571
DELISTED
Diebold Nixdorf Incorporated
DBD
| $2.66M | ﹤0.01% |
237,706
+9,675
| +4% | +$115K |
|
|
PRO
1572
DELISTED
PROS Holdings
PRO
| $2.66M | ﹤0.01% |
44,588
-1,866
| -4% | -$126K |
|
|
XLRN
1573
DELISTED
Acceleron Pharma
XLRN
| $2.66M | ﹤0.01% |
67,236
+2,186
| +3% | +$94.8K |
|
|
PTLA
1574
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.65M | ﹤0.01% |
98,863
+6,426
| +7% | +$180K |
|
1575
Buckle
BKE
$2.35B
| $2.65M | ﹤0.01% |
128,635
+2,960
| +2% | +$56.9K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2019 Portfolio in Review
As of Q3 2019, RhumbLine Advisers held 3,009 positions worth $54.7B, up 2.7% from $53.3B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Trading was light in Q3 2019: portfolio turnover was 3.1%. RhumbLine Advisers opened 39 new positions and exited 55, leaving the 3,009-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2019 buy was Avantor: 187,780 shares worth $2.76M.
- RhumbLine Advisers added most to Fidelity National Information Services in Q3 2019, an estimated $65.3M increase.
- RhumbLine Advisers's biggest Q3 2019 reduction was Leidos, cutting an estimated $15M.
- RhumbLine Advisers fully exited Anadarko Petroleum in Q3 2019, selling an estimated $64.3M.
- RhumbLine Advisers's ten largest holdings make up 17% of its $54.7B portfolio in Q3 2019.
- RhumbLine Advisers opened 39 new positions and closed 55 in Q3 2019.
- RhumbLine Advisers's portfolio value rose 2.7% quarter-over-quarter to $54.7B.
Based on RhumbLine Advisers's 13F filing for Q3 2019, filed 23 Oct 2019.